Published October 22, 2012 | Version v1
Journal article

Outcome and patterns of failure after postoperative intensity modulated radiotherapy for locally advanced or high-risk oral cavity squamous cell carcinoma

  • 1. Department of Radiation Oncology and Division of Medical Radiation Physics, Bern University Hospital, Freiburgstrasse, 3010, Bern (Switzerland)
  • 2. SAKK Coordinating Center, Effingerstrasse 40, 3008, Bern (Switzerland)
  • 3. Department of Otorhinolaryngology, University Hospital Bern, Freiburgstrasse, 3010, Bern (Switzerland)
  • 4. Department of Craniomaxillofacial Surgery, University Hospital Bern, Freiburgstrasse, 3010, Bern (Switzerland)

Description

To determine the outcome and patterns of failure in oral cavity cancer (OCC) patients after postoperative intensity modulated radiotherapy (IMRT) with concomitant systemic therapy. All patients with locally advanced (AJCC stage III/IV) or high-risk OCC (AJCC stage II) who underwent postoperative IMRT at our institution between December 2006 and July 2010 were retrospectively analyzed. The primary endpoint was locoregional recurrence-free survival (LRRFS). Secondary endpoints included distant metastasis-free survival (DMFS), overall survival (OS), acute and late toxicities. Overall 53 patients were analyzed. Twenty-three patients (43%) underwent concomitant chemotherapy with cisplatin, two patients with carboplatin (4%) and four patients were treated with the monoclonal antibody cetuximab (8%). At a median follow-up of 2.3 (range, 1.1–4.6) years the 3-year LRRFS, DMFS and OS estimates were 79%, 90%, and 73% respectively. Twelve patients experienced a locoregional recurrence. Eight patients, 5 of which had both a flap reconstruction and extracapsular extension (ECE), showed an unusual multifocal pattern of recurrence. Ten locoregional recurrences occurred marginally or outside of the high-risk target volumes. Acute toxicity grades of 2 (27%) and 3 (66%) and late toxicity grades of 2 (34%) and 3 (11%) were observed. LRRFS after postoperative IMRT is satisfying and toxicity is acceptable. The majority of locoregional recurrences occurred marginally or outside of the high-risk target volumes. Improvement of high-risk target volume definition especially in patients with flap reconstruction and ECE might transfer into better locoregional control

Availability note (English)

Available from http://dx.doi.org/10.1186/1748-717X-7-175; Available from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3551735

Additional details

Publishing Information

Journal Title
Radiation Oncology (Online)
Journal Volume
7
Journal Page Range
p. 175
ISSN
1748-717X

INIS

Country of Publication
United Kingdom
Country of Input or Organization
International Atomic Energy Agency (IAEA)
INIS RN
47062012
Subject category
S62: RADIOLOGY AND NUCLEAR MEDICINE;
Descriptors DEI
CARCINOMAS; CHEMOTHERAPY; FAILURES; MONOCLONAL ANTIBODIES; ORAL CAVITY; PATIENTS; RADIOTHERAPY; TOXICITY
Descriptors DEC
ANTIBODIES; DIGESTIVE SYSTEM; DISEASES; MEDICINE; NEOPLASMS; NUCLEAR MEDICINE; RADIOLOGY; THERAPY

Optional Information

Copyright
Copyright (c)2012 Geretschl#Latin Small Letter A With Diaeresis#ger et al.
Notes
PMCID: PMC3551735; PUBLISHER-ID: 1748-717X-7-175; PMID: 23088283; OAI: oai:pubmedcentral.nih.gov:3551735; licensee BioMed Central Ltd.